164 related articles for article (PubMed ID: 26169402)
1. Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murine macrophages.
Peyrusson F; Butler D; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2015 Sep; 59(9):5747-60. PubMed ID: 26169402
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
Hoover J; Lewandowski T; Straub RJ; Novick SJ; DeMarsh P; Aubart K; Rittenhouse S; Zalacain M
Antimicrob Agents Chemother; 2016 Jan; 60(1):180-9. PubMed ID: 26482300
[TBL] [Abstract][Full Text] [Related]
3. Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells.
Peyrusson F; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358297
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322.
O'Dwyer K; Hackel M; Hightower S; Hoban D; Bouchillon S; Qin D; Aubart K; Zalacain M; Butler D
Antimicrob Agents Chemother; 2013 May; 57(5):2333-42. PubMed ID: 23478958
[TBL] [Abstract][Full Text] [Related]
5. Cellular pharmacokinetics and intracellular activity of the bacterial fatty acid synthesis inhibitor, afabicin desphosphono against different resistance phenotypes of Staphylococcus aureus in models of cultured phagocytic cells.
Peyrusson F; Van Wessem A; Dieppois G; Van Bambeke F; Tulkens PM
Int J Antimicrob Agents; 2020 Feb; 55(2):105848. PubMed ID: 31770623
[TBL] [Abstract][Full Text] [Related]
6. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
[TBL] [Abstract][Full Text] [Related]
7. Potent sub-MIC effect of GSK1322322 and other peptide deformylase inhibitors on in vitro growth of Staphylococcus aureus.
Butler D; Chen D; O'Dwyer K; Lewandowski T; Aubart K; Zalacain M
Antimicrob Agents Chemother; 2014; 58(1):290-6. PubMed ID: 24165188
[TBL] [Abstract][Full Text] [Related]
8. RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria.
Buyck JM; Peyrusson F; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2015 Aug; 59(8):4750-8. PubMed ID: 26014952
[TBL] [Abstract][Full Text] [Related]
9. Frequency of Spontaneous Resistance to Peptide Deformylase Inhibitor GSK1322322 in Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae.
Min S; Ingraham K; Huang J; McCloskey L; Rilling S; Windau A; Pizzollo J; Butler D; Aubart K; Miller LA; Zalacain M; Holmes DJ; O'Dwyer K
Antimicrob Agents Chemother; 2015 Aug; 59(8):4644-52. PubMed ID: 26014938
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
Lemaire S; Van Bambeke F; Mingeot-Leclercq MP; Tulkens PM
Antimicrob Agents Chemother; 2007 Aug; 51(8):2748-57. PubMed ID: 17548493
[TBL] [Abstract][Full Text] [Related]
11. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin.
Brinch KS; Tulkens PM; Van Bambeke F; Frimodt-Møller N; Høiby N; Kristensen HH
J Antimicrob Chemother; 2010 Aug; 65(8):1720-4. PubMed ID: 20534628
[TBL] [Abstract][Full Text] [Related]
12. Reducing Antibacterial Development Risk for GSK1322322 by Exploring Potential Human Dose Regimens in Nonclinical Efficacy Studies Using Immunocompetent Rats.
Hoover JL; Singley CM; Elefante P; DeMarsh P; Zalacain M; Rittenhouse S
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807913
[TBL] [Abstract][Full Text] [Related]
13. Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor.
Naderer OJ; Dumont E; Zhu J; Kurtinecz M; Jones LS
Antimicrob Agents Chemother; 2013 May; 57(5):2005-9. PubMed ID: 23403431
[TBL] [Abstract][Full Text] [Related]
14. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.
Vallet CM; Marquez B; Ngabirano E; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2011 Sep; 38(3):249-56. PubMed ID: 21764262
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor.
Naderer OJ; Jones LS; Zhu J; Kurtinecz M; Dumont E
J Clin Pharmacol; 2013 Nov; 53(11):1168-76. PubMed ID: 23907665
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages.
Barcia-Macay M; Seral C; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2006 Mar; 50(3):841-51. PubMed ID: 16495241
[TBL] [Abstract][Full Text] [Related]
17. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: a randomized placebo-controlled study.
Naderer OJ; Dumont E; Zhu J; Kurtinecz M; Jones LS
J Antimicrob Chemother; 2013 Aug; 68(8):1901-9. PubMed ID: 23557930
[TBL] [Abstract][Full Text] [Related]
19. Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes.
Van de Velde S; Nguyen HA; Van Bambeke F; Tulkens PM; Grellet J; Dubois V; Quentin C; Saux MC
J Antimicrob Chemother; 2008 Sep; 62(3):518-21. PubMed ID: 18544595
[TBL] [Abstract][Full Text] [Related]
20. Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus.
Nguyen HA; Grellet J; Dubois V; Saux MC; Quentin C
J Antimicrob Chemother; 2007 Apr; 59(4):755-8. PubMed ID: 17353222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
